Unraveling ADC resistance in hematologic malignancies: Challenges and new frontiers

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Antibody-drug conjugates (ADCs) represent a significant therapeutic advance for hematologic malignancies, offering targeted cell killing with reduced systemic toxicity.
• Despite initial successes, the development of resistance to ADCs poses a major obstacle to their sustained clinical benefit in treating blood cancers.

Purpose of the Study:

• To comprehensively review the diverse mechanisms driving resistance to antibody-drug conjugates (ADCs) in hematologic cancers.
• To explore the influence of the tumor microenvironment on ADC efficacy and resistance.
• To highlight emerging strategies aimed at overcoming ADC resistance for improved patient outcomes.

Main Methods:

• Literature review of studies investigating antibody-drug conjugate (ADC) resistance in hematologic malignancies.
• Analysis of molecular mechanisms contributing to ADC resistance, including cellular and microenvironmental factors.
• Synthesis of current and future therapeutic strategies to combat ADC resistance.

Main Results:

• Key resistance mechanisms identified include efflux pump overexpression, antigen downregulation, impaired drug trafficking, and altered apoptosis.
• The tumor microenvironment plays a critical role in fostering resistance and diminishing ADC effectiveness.
• Emerging strategies involve combination therapies, novel ADC designs, and biomarker-guided patient selection.

Conclusions:

• Understanding the multifaceted mechanisms of ADC resistance is essential for optimizing current treatments.
• Developing strategies to overcome resistance is crucial for enhancing the long-term efficacy of ADCs in hematologic malignancies.
• Future research should focus on personalized approaches and next-generation ADCs to improve patient responses.